Shukra Pharmaceuticals' record carries a clean audit opinion for the last four years, but that clean opinion sits on top of a recurring pattern of regulatory breaches, undisclosed tax exposure, and profit driven by management judgment. The most serious issues: a preferential warrant allotment that missed SEBI deadlines, an income-tax contingent liability of undisclosed size carried for six years while a rights document declared all litigation nil, and operating cash flow that fell to a fraction of reported profit in FY26.
Key findings
- Preferential warrant allotment breached SEBI timelines, forcing fresh approval
Major- The company allotted 46,43,000 convertible equity warrants to promoters on 28 January 2026, beyond the timeline under Regulation 170(1) of the SEBI ICDR Regulations, requiring fresh shareholder approval under Regulation 170(2). The original allotment price was ₹34 per warrant, later re-computed to ₹35.56 per warrant with a fresh Relevant Date of June 5, 2026, per the 12 Jun 2026 announcement. The Board's Report also stated no strictures were imposed by SEBI in the last three years, though BSE fined the company ₹1,82,000 for a bonus-share delay, paid on 4 March 2024. - Audit opinions turned clean, but the underlying issues persisted for years
Major- Auditors issued qualified opinions in FY2019-20, FY2020-21 and FY2021-22 on interest-free related-party loans and unpaid dividend tax, before issuing clean opinions from FY2022-23 onward. CARO reported an interest-free loan overdue beyond 90 days with no recovery steps in FY2022-23 and FY2023-24, and an income-tax demand of ₹1.4 crore from March 2023 through March 2025 that increased to ₹5.79 crore by March 2026. CARO also reported CSR non-compliance in FY2024-25, and the FY2023-24 secretarial audit raised six qualifications, including unpublished financial results and unfiled statutory forms. - Income-tax contingent liability disclosed at ₹139.91 lakh, rising to ₹578.14 lakh, while a rights document declared litigation nil
Major- For every year from FY2022-23 through FY2025-26, the company disclosed matters pending before Income Tax Authorities where it had filed neither an appeal nor a response to the demand. The disclosed amount was ₹139.91 lakh for FY2022-23 through FY2024-25, rising to ₹578.14 lakh in FY2025-26. The rights issue Draft Letter of Offer dated 28 September 2024 disclosed nil litigation in all categories, including tax liabilities and statutory violations. The company has not provided for these as contingent liabilities, stating no material adverse effect is expected. - Profit surge rests on management judgment calls, with copy-paste errors in policy notes
Major- Management attributed the FY2025-26 profit jump to expenses "no more effected even though sales is increased". In FY2019-20 and FY2020-21, other income included liabilities written back "as per the best assumption and decision of the management". The FY2021-22 tax policy note erroneously describes "Sakar Healthcare Limited" as the company, and the FY2022-23 report states Ind AS amendments were first applied from April 01, 2021, inconsistent with that report's year. - Recurring interest-free related-party loans, twice flagged as prejudicial
Major- Auditors qualified FY2019-20 and FY2020-21 opinions because interest-free loans to related parties had terms prima facie prejudicial to the company's interest, with no repayment schedule. CARO reported an interest-free loan overdue beyond 90 days with no recovery steps in FY2023-24. Unsecured loans from related parties were repayable on demand and interest-free in FY2021-22 through FY2025-26. The FY2023-24 Board's Report stated no related party transactions were entered into that year. - Promoter family holds multiple executive roles with nil pay, while MD remuneration was repeatedly raised
Major- The Managing Director's remuneration was raised from ₹25,92,000 to ₹57,60,000 per annum in September 2022, then to ₹96,00,000 per annum in March 2024, citing "inadequacy of profits". The MD's wife and son were appointed Whole-time and Executive Directors with nil or board-determined remuneration. KMP remuneration rose 59.83% in FY2022-23 versus 7.32% for other employees, and 53.06% in FY2024-25 versus 32.46%. - Borrowings are modest and fully disclosed, with no hidden debt
Clean- The company borrowed ₹2.47 crore in FY2025-26, with car and working-capital loan rates between 7.25% and 12.00%. CARO for FY2023-24 confirmed no repayment defaults, no wilful-defaulter status, and no diversion of funds. No one-time settlement of loans occurred in FY2025-26.
What to watch
- Warrant approval and payment. Fresh shareholder approval for the 46,43,000 warrants allotted 28 January 2026 was disclosed 12 June 2026; the balance 75% payment is due within 18 months of allotment.
- Income-tax matters. Outcome of pending Income Tax Authority matters where no appeal or response has been filed, as disclosed in the FY2025-26 Annual Report.
- GST assessment. Completion of GST assessment proceedings under process, as disclosed in the FY2025-26 Annual Report.
- Cash flow recovery. FY2026-27 annual results, to test whether CFO/PAT recovers from the 0.18x reported for FY26.
- Deferred tax and MAT credit. Next annual report (FY2026-27), whether the MAT credit and deferred tax assets are utilized or reversed, given management's stated reliance on "convincing evidence of future normal tax payment".
- New ventures. Completion of the proposed B&S Robotics JV with Borns Singapore, announced 14 August 2026, and capital deployment across nine subsidiaries incorporated in FY2025-26.
Bottom line: This is a company with modest, cleanly disclosed borrowings and no hidden debt, but the clean audit opinions of recent years mask a record of recurring compliance lapses and disclosure contradictions. The risk character is one of management judgment driving reported profit, through warrant pricing inconsistencies, undisclosed tax exposure, and cash flow that lags reported earnings, while related-party financing and family governance remain constant features. Watch the warrant approval, the tax outcomes, and whether operating cash flow catches up with reported profit.